staurosporine has been researched along with ldn 193189 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Daniels, RN; Gentry, PR; Hao, J; Ho, JN; Hong, CC; Hopkins, CR; Karim, KA; Lewis, JA; Lindsley, CW | 1 |
| Amin, S; Jaiswal, AS; Law, BK; Narayan, S; Ramisetti, S; Sharma, AK; Singh, P; Singh-Pillay, A | 1 |
2 other study(ies) available for staurosporine and ldn 193189
| Article | Year |
|---|---|
In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors.
Topics: Animals; Bone Morphogenetic Proteins; Drug Evaluation, Preclinical; Embryo, Nonmammalian; Pyrazoles; Pyrimidines; Quinolines; Structure-Activity Relationship; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Zebrafish | 2010 |
ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
Topics: Adamantane; Antineoplastic Agents; Aza Compounds; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Molecular Structure; Oxaliplatin; Stem Cells; Structure-Activity Relationship; Tumor Cells, Cultured | 2019 |